This Week in Hearing

ELEHEAR is positioning itself as a forward-thinking player in the OTC hearing aid market, evolving from an OEM supplier to a direct-to-consumer brand focused on accessibility and innovation. Shari Eberts talks with Jalene Nadeau, Chief Audiologist & Director of Customer Support at ELEHEAR, about the company’s strategic shift and their efforts to make high-quality hearing technology widely available. Jalene explains

How can AI make the journey to better hearing smoother for OTC hearing aid users? In this episode from the EUHA show floor, Tuned co-founders Omri Gavish and Ron Ganot, joined by Board Advisor Delain Wright, discuss their recent collaboration with JVC to introduce hearing aids equipped with streaming and rechargeability. More importantly, they reveal Tuned’s AI-based care model, which

Rally Caps is not just another baseball movie—it’s a powerful story about overcoming adversity, friendship, and authentic representation of hearing loss. In this episode, Shari Eberts speaks with Jodi Cutler, co-author of the book that inspired the film, and Lee Cipolla, the film’s director. Rally Caps follows Jordy, a young baseball player with cochlear implants, and Lucas, his teammate and

What will audiology look like in 2050? In this insightful discussion, Doctors Amyn Amlani and Jason Leyendecker sit down with Dave Kemp to explore the Audiology 2050 initiative, a visionary roadmap from the Academy of Doctors of Audiology (ADA) aiming to elevate the profession to meet future challenges. Born from a thorough review of audiology’s history and current challenges, Audiology

OTOPLAN©, a specialized tool for surgeons and audiologists, enables 3D reconstruction of a patient’s cochlea using CT and MRI scans. This capability optimizes electrode array selection before surgery and enhances implant programming afterward. Since achieving FDA clearance in the U.S., OTOPLAN has been adopted by over 225 clinical centers, processing more than 3,200 scans and providing clinicians with precise anatomical

How does audiology intersect with the legal system? Dr. Robert Traynor, an expert in forensic audiology, delves into this unique area where audiologists apply their knowledge to assist in legal cases involving hearing loss, tinnitus, and injury claims. Dr. Traynor, inspired by Marc Kramer’s 1982 book Forensic Audiology, explains how forensic audiologists help attorneys and courts understand complex auditory issues,

What if we could dramatically accelerate the process of turning tinnitus research into real-world clinical solutions? In this discussion, Jeffery Reagan and Dr. James Henry introduce the idea of a Tinnitus Learning Health Network, a collaborative model aimed at bridging the gap between research, clinical practice, and patient experiences. By fostering open communication and collaboration among these groups, the network

Starkey’s Dave Fabry and Achin Bhowmik delve into the advanced capabilities of the Edge AI hearing aids, discussing the improvements over the previous Genesis AI model. They highlight the always-on deep neural network (DNN), which continuously adapts to different sound environments, offering a seamless experience for users. The Edge mode feature has been enhanced, allowing users to boost speech clarity

Building on their reputation as a direct-to-consumer innovator, Eargo is now entering the prescriptive hearing aid market, offering patients and audiologists a new level of control and care with their cutting-edge devices. CEO Bill Brownie reflects on Eargo’s journey, highlighting how their invisible, rechargeable devices have evolved to meet the demands of patients who want both cutting-edge technology and expert

Jian Zuo, CEO of Ting Therapeutics, discusses the latest updates on otoprotective agents for three conditions: antibiotic-induced hearing loss, cisplatin-induced hearing loss, and noise-induced hearing loss. Dr. Zuo explains the science behind the company’s innovative drug candidates and how they aim to address the unmet need for hearing protection. He provides an overview of Ting Therapeutics’ preclinical research, outlining key